{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:27:32Z","timestamp":1790908052611,"version":"4.1.0"},"reference-count":32,"publisher":"Walter de Gruyter GmbH","issue":"12","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_cclm-2025-0137_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Autoantibodies against structure elements of the pancreas are an essential part of laboratory diagnosis of diabetes mellitus. The heterogeneity of current methods and difficult inter-assay comparability of results poses challenges to both clinical interpretation as well as research integrity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0137_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a method validation study comparing the measurement of autoantibodies against glutamic acid decarboxylase (GADA), islet antigen 2 (IA-2A), and zinc transporter 8 (ZnT8A) on three commercially available platforms (EUROLabWorkstation analyzer, enzyme-linked immunosorbent assay (ELISA); iFlash 1800 (chemiluminescence immunoassay (CLIA); Maglumi 800 (CLIA)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0137_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to the results from EUROLabWorkstation analyzer that was routinely used in our laboratory, the Maglumi demonstrated an acceptable agreement and deviation for GADA (75.4\u221235.8\u202f%) and IA-2A (71.7\u221250.3\u202f%). The iFlash displayed less favorable results with agreement and deviation for GADA (51.5\u2212108.8\u202f%) and IA-2A (68\u221232.5\u202f%). While the iFlash showed excellent agreement for ZnT8A, the Maglumi produced almost exclusively negative results below a 200\u202fU\/mL threshold which results in severe underestimation of results on the Maglumi. Overall, no consistent agreement was observed across all three parameters among the CLIA devices tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_cclm-2025-0137_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study reveals significant and clinically relevant discrepancies in the detection of GADA and IA-2A when comparing CLIA devices to the ELISA method routinely used in our laboratory. For individual antibodies up to 65\u202f% of patients who tested positive using ELISA showed negative or borderline results on at least one CLIA device. These deviations are unpredictable and cannot be detected through standard calibration and internal control procedures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/cclm-2025-0137","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T05:58:26Z","timestamp":1755842306000},"page":"2568-2577","source":"Crossref","is-referenced-by-count":4,"title":["Method comparison of diabetes mellitus associated autoantibodies in serum specimens"],"prefix":"10.1515","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1317-3603","authenticated-orcid":false,"given":"Alexander","family":"Lenard","sequence":"first","affiliation":[{"name":"MVZ Labor Dr. Limbach & Kollegen eGbR , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rapp","sequence":"additional","affiliation":[{"name":"MVZ Labor Dr. Limbach & Kollegen eGbR , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Busch","sequence":"additional","affiliation":[{"name":"MVZ Labor Dr. Limbach & Kollegen eGbR , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Findeisen","sequence":"additional","affiliation":[{"name":"MVZ Labor Dr. Limbach & Kollegen eGbR , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2025110712102433852_j_cclm-2025-0137_ref_001","doi-asserted-by":"crossref","unstructured":"Chiang, JL, Kirkman, MS, Laffel, LM, Peters, AL, Type 1 Diabetes Sourcebook, A. Type 1 diabetes through the life span: a position statement of the American diabetes association. Diabetes Care 2014;37:2034\u201354. https:\/\/doi.org\/10.2337\/dc14-1140.","DOI":"10.2337\/dc14-1140"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_002","doi-asserted-by":"crossref","unstructured":"Ahlqvist, E, Storm, P, Karajamaki, A, Martinell, M, Dorkhan, M, Carlsson, A, et al.. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018;6:361\u20139. https:\/\/doi.org\/10.1016\/s2213-8587-18-30051-2.","DOI":"10.1016\/S2213-8587(18)30051-2"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_003","doi-asserted-by":"crossref","unstructured":"H\u00f6rber, S, Heni, M, Peter, A. [Laboratory diagnostics of people with diabetes]. 2022;18(1):77\u201386.","DOI":"10.1007\/s11428-021-00813-0"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_004","doi-asserted-by":"crossref","unstructured":"Naik, RG, Brooks-Worrell, BM, Palmer, JP. Latent autoimmune diabetes in adults. J\u00a0Clin Endocrinol Metab 2009;94:4635\u201344. https:\/\/doi.org\/10.1210\/jc.2009-1120.","DOI":"10.1210\/jc.2009-1120"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_005","doi-asserted-by":"crossref","unstructured":"Leslie, RD, Williams, R, Pozzilli, P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J\u00a0Clin Endocrinol Metab 2006;91:1654\u20139. https:\/\/doi.org\/10.1210\/jc.2005-1623.","DOI":"10.1210\/jc.2005-1623"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_006","doi-asserted-by":"crossref","unstructured":"Maruyama, T, Nakagawa, T, Kasuga, A, Murata, M. Heterogeneity among patients with latent autoimmune diabetes in adults. Diabetes Metab Res Rev 2011;27:971\u20134. https:\/\/doi.org\/10.1002\/dmrr.1238.","DOI":"10.1002\/dmrr.1238"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_007","doi-asserted-by":"crossref","unstructured":"Niskanen, LK, Tuomi, T, Karjalainen, J, Groop, LC, Uusitupa, MI. GAD antibodies in NIDDM. ten-year follow-up from the diagnosis. Diabetes Care 1995;18:1557\u201365. https:\/\/doi.org\/10.2337\/diacare.18.12.1557.","DOI":"10.2337\/diacare.18.12.1557"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_008","doi-asserted-by":"crossref","unstructured":"Falorni, A, Gambelunghe, G, Forini, F, Kassi, G, Cosentino, A, Candeloro, P, et al.. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J\u00a0Clin Endocrinol Metab 2000;85:309\u201316. https:\/\/doi.org\/10.1210\/jcem.85.1.6301.","DOI":"10.1210\/jc.85.1.309"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_009","doi-asserted-by":"crossref","unstructured":"Borg, H, Gottsater, A, Landin-Olsson, M, Fernlund, P, Sundkvist, G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J\u00a0Clin Endocrinol Metab 2001;86:3032\u20138. https:\/\/doi.org\/10.1210\/jcem.86.7.7658.","DOI":"10.1210\/jcem.86.7.7658"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_010","doi-asserted-by":"crossref","unstructured":"Zhu, Y, Qian, L, Liu, Q, Zou, J, Zhou, Y, Yang, T, et al.. Glutamic acid decarboxylase autoantibody detection by electrochemiluminescence Assay identifies latent autoimmune diabetes in adults with poor islet function. Diabetes Metab J 2020;44:260\u20136. https:\/\/doi.org\/10.4093\/dmj.2019.0007.","DOI":"10.4093\/dmj.2019.0007"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_011","doi-asserted-by":"crossref","unstructured":"Fan, B, Lim, CKP, Poon, EWM, Lau, ESH, Wu, H, Yang, A, et al.. Differential associations of GAD antibodies (GADA) and C-Peptide with insulin initiation, glycemic responses, and severe hypoglycemia in patients diagnosed with type 2 diabetes. Diabetes Care 2023;46:1282\u201391. https:\/\/doi.org\/10.2337\/dc22-2301.","DOI":"10.2337\/dc22-2301"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_012","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C. 2, Aleppo, G, Bannuru, RR, Bruemmer, D, Collins, BS, Ekhlaspour, L, et al.. Diagnosis and classification of diabetes: standards of care in Diabetes-2024. Diabetes Care 2024;47:S20\u201342. https:\/\/doi.org\/10.2337\/dc24-s002.","DOI":"10.2337\/dc24-S002"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_013","doi-asserted-by":"crossref","unstructured":"Harris, MI, Robbins, DC. Prevalence of adult-onset IDDM in the U.S. population. Diabetes Care 1994;17:1337\u201340. https:\/\/doi.org\/10.2337\/diacare.17.11.1337.","DOI":"10.2337\/diacare.17.11.1337"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_014","doi-asserted-by":"crossref","unstructured":"Landin-Olsson, M, Nilsson, KO, Lernmark, A, Sundkvist, G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990;33:561\u20138. https:\/\/doi.org\/10.1007\/bf00404145.","DOI":"10.1007\/BF00404145"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_015","doi-asserted-by":"crossref","unstructured":"Cervin, C, Lyssenko, V, Bakhtadze, E, Lindholm, E, Nilsson, P, Tuomi, T, et al.. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008;57:1433\u20137. https:\/\/doi.org\/10.2337\/db07-0299.","DOI":"10.2337\/db07-0299"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_016","doi-asserted-by":"crossref","unstructured":"Lukacs, K, Hosszufalusi, N, Dinya, E, Bakacs, M, Madacsy, L, Panczel, P. The type 2\u00a0diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the gene effect is modified by obesity: a meta-analysis and an individual study. Diabetologia 2012;55:689\u201393. https:\/\/doi.org\/10.1007\/s00125-011-2378-z.","DOI":"10.1007\/s00125-011-2378-z"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_017","doi-asserted-by":"crossref","unstructured":"Pettersen, E, Skorpen, F, Kvaloy, K, Midthjell, K, Grill, V. Genetic heterogeneity in latent autoimmune diabetes is linked to various degrees of autoimmune activity: results from the nord-trondelag health study. Diabetes 2010;59:302\u201310. https:\/\/doi.org\/10.2337\/db09-0923.","DOI":"10.2337\/db09-0923"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_018","doi-asserted-by":"crossref","unstructured":"Chang, DC, Piaggi, P, Hanson, RL, Knowler, WC, Bucci, J, Thio, G, et al.. Use of a high-density protein microarray to identify autoantibodies in subjects with type 2 diabetes mellitus and an HLA background associated with reduced insulin secretion. PLoS One 2015;10:e0143551. https:\/\/doi.org\/10.1371\/journal.pone.0143551.","DOI":"10.1371\/journal.pone.0143551"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_019","doi-asserted-by":"crossref","unstructured":"Brooks-Worrell, B, Hampe, CS, Hattery, EG, Palomino, B, Zangeneh, SZ, Utzschneider, K, et al.. Islet autoimmunity is highly prevalent and associated with diminished beta-cell function in patients with type 2 diabetes in the grade study. Diabetes 2022;71:1261\u201371. https:\/\/doi.org\/10.2337\/db21-0590.","DOI":"10.2337\/figshare.18621602.v1"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_020","doi-asserted-by":"crossref","unstructured":"Kricka, LJ, Kaur, R, Malik, AK. Chemiluminescence. Cold Spring Harb Protoc 2018;2018. https:\/\/doi.org\/10.1007\/978-981-10-4702-2-22.","DOI":"10.1101\/pdb.top098236"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_021","doi-asserted-by":"crossref","unstructured":"Khan, MSS, Salman, M, Abdullah, M, Hayat, F, Akbar, S. Enzyme-linked immunosorbent assay versus chemiluminescent immunoassay: a general overview. Glob J Med Pharm Biomed Update 2023;18:1.","DOI":"10.25259\/GJMPBU_77_2022"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_022","doi-asserted-by":"crossref","unstructured":"Kawasaki, E, Uga, M, Nakamura, K, Kuriya, G, Satoh, T, Fujishima, K, et al.. Association between anti-ZnT8 autoantibody specificities and SLC30A8 Arg325Trp variant in Japanese patients with type 1 diabetes. Diabetologia 2008;51:2299\u2013302. https:\/\/doi.org\/10.1007\/s00125-008-1165-y.","DOI":"10.1007\/s00125-008-1165-y"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_023","doi-asserted-by":"crossref","unstructured":"Wenzlau, JM, Frisch, LM, Hutton, JC, Davidson, HW. Mapping of conformational autoantibody epitopes in ZNT8. Diabetes Metab Res Rev 2011;27:883\u20136. https:\/\/doi.org\/10.1002\/dmrr.1266.","DOI":"10.1002\/dmrr.1266"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_024","doi-asserted-by":"crossref","unstructured":"Wenzlau, JM, Juhl, K, Yu, L, Moua, O, Sarkar, SA, Gottlieb, P, et al.. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 2007;104:17040\u20135. https:\/\/doi.org\/10.1073\/pnas.0705894104.","DOI":"10.1073\/pnas.0705894104"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_025","doi-asserted-by":"crossref","unstructured":"Wenzlau, JM, Liu, Y, Yu, L, Moua, O, Fowler, KT, Rangasamy, S, et al.. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008;57:2693\u20137. https:\/\/doi.org\/10.2337\/db08-0522.","DOI":"10.2337\/db08-0522"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_026","doi-asserted-by":"crossref","unstructured":"Musso, G, Zoccarato, M, Gallo, N, Padoan, A, Cosma, C, Zuliani, L, et al.. Analytical evaluation of a GAD65 antibodies chemiluminescence immunoassay for CSF in neurological syndromes. Clin Chem Lab Med 2023;61:1802\u20137. https:\/\/doi.org\/10.1515\/cclm-2023-0072.","DOI":"10.1515\/cclm-2023-0072"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_027","doi-asserted-by":"crossref","unstructured":"Cosma, C, Padoan, A, Plebani, M. Evaluation of precision, comparability and linearity of MAGLUMI\u2122 2000 plus GAD65 antibody assay. J\u00a0Lab Precis Med 2019;4. https:\/\/doi.org\/10.21037\/jlpm.2019.09.03.","DOI":"10.21037\/jlpm.2019.09.03"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_028","doi-asserted-by":"crossref","unstructured":"Lapic, I, Kralik Oguic, S, Rogic, D. Preliminary evaluation of eight less frequent endocrine assays designed for MAGLUMI 800 chemiluminescence immunoanalyzer. Scand J Clin Lab Invest 2021;81:332\u20138. https:\/\/doi.org\/10.1080\/00365513.2021.1908590.","DOI":"10.1080\/00365513.2021.1908590"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_029","doi-asserted-by":"crossref","unstructured":"Ziobrowska-Bech, A, Winther-Larsen, A, Kremke, B, Parkner, T, Soendersoe Knudsen, C. Reference limits for GAD65 and IA-2\u00a0autoantibodies by chemiluminescence immunoassay in Northern\u00a0European adults and children. Scand J Clin Lab Invest 2019;79:123\u20135. https:\/\/doi.org\/10.1080\/00365513.2019.1566566.","DOI":"10.1080\/00365513.2019.1566566"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_030","doi-asserted-by":"crossref","unstructured":"Larsen, JB, Knudsen, CS, Parkner, T. Procollagen III, N-terminal propeptide (PIIINP): establishment of reference intervals in Northern European adults and children using the MAGLUMI 800 chemiluminescence immunoassay. Scand J Clin Lab Invest 2021;81:389\u201393. https:\/\/doi.org\/10.1080\/00365513.2021.1929444.","DOI":"10.1080\/00365513.2021.1929444"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_031","doi-asserted-by":"crossref","unstructured":"Lippi, G, Salvagno, GL, Gelati, M, Pucci, M, Lo Cascio, C, Demonte, D, et al.. Two-center comparison of 10\u00a0fully-automated commercial procalcitonin (PCT) immunoassays. Clin Chem Lab Med 2019;58:77\u201384. https:\/\/doi.org\/10.1515\/cclm-2019-0888.","DOI":"10.1515\/cclm-2019-0888"},{"key":"2025110712102433852_j_cclm-2025-0137_ref_032","doi-asserted-by":"crossref","unstructured":"Faccinetti, NI, Guerra, LL, Penas Steinhardt, A, Iacono, RF, Frechtel, GD, Trifone, L, et al.. Characterization of zinc transporter 8 (ZnT8) antibodies in autoimmune diabetic patients from Argentinian population using monomeric, homodimeric, and heterodimeric ZnT8 antigen variants. Eur J Endocrinol 2016;174:157\u201365. https:\/\/doi.org\/10.1530\/eje-15-0681.","DOI":"10.1530\/EJE-15-0681"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0137\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:11:53Z","timestamp":1762517513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0137\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,16]]},"published-print":{"date-parts":[[2025,11,25]]}},"alternative-id":["10.1515\/cclm-2025-0137"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0137","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}